Chronic Kidney Disease Augments Gout Risks

By Jack Cush, MD | 09 April 2019

A population based cohort analysis shows that patients with incident gout and chronic kidney disease (CKD) have far worse outcomes than those without CKD.

A retrospective population-based cohort study of incident gout between 2006-2009 identified those with CKD; defined as a pre-existing diagnosis of chronic kidney disease, chronic renal failure, kidney transplantation, or dialysis at index date.

Among 12,940 incident adult gout patients, 64% with CKD and 36% without CKD, were followed for 55,206 person-years.

Overall, gout patients with CKD (vs those without CKD) had:

Significantly more healthcare utilization; Hospital admissions were at least 3 times higher for Gout+CKD adults < 55 (mean = 0.51 vs 0.13) and approximately 1.5 times higher for adults 55+ (mean = 0.46 vs 0.29) without CKD.
All-cause mortality was higher among those with CKD compared to those without CKD for both age groups (HR< 55 years = 1.65; 95% CI 1.01-2.71; HR55+ years = 1.50; 95% CI 1.37-1.65).

Gout plus CKD constitutes a high risk population that merits focused efforts to better control their gout and optimize comorbidity management.

Disclosures:

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may Login/Register to comment.

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

[...]

A Role for SGLT2 Inhibition in Gout?

By MedPage Today | 17 Dec 2019

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

[...]

Predicting Inpatient Gout Flares

By Jack Cush, MD | 13 Dec 2019

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

[...]

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

By Olga Petryna, MD | 25 Nov 2019

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

By Olga Petryna, MD | 20 Nov 2019

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

You are here